INTELLIA THERAPEUTICS INC (NTLA)
US45826J1051 - Common Stock
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET.
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion.
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free...
First Week of June 21st Options Trading For Intellia Therapeutics (NTLA)
2 Stocks Down 30% to Buy Right Now
These stocks have plenty of catalysts ahead.
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
These two stocks could be ripe for a rebound.
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term.
Better Cathie Wood Stock: Moderna vs. Intellia
Moderna and Intellia have declined in the double digits over the past year.
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now.
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Is Intellia Therapeutics Stock a Buy Now?
The company's future will depend on its innovative qualities.
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
2024 could see the start of its first late-stage clinical trials.
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The futures for these two beaten-down stocks could be brighter than their recent pasts.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular money manager added to these three existing positions on Monday following disappointing financial updates earlier this month.
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in...
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
These exciting players could deliver explosive growth over time.
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Good news may be on the way, but it will be a while before it arrives.
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting...
Crispr, Intellia, and Recursion gain as Ark ETFs boost stakes
Cathie Wood-run Ark ETFs lift stakes in gene editing biotechs CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and AI-focused Recursion (RXRX). Read more here.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor keeps making moves.
A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist
These biotech innovators have what it takes to soar.
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single dose A single...
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example.
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
Expectations for these stocks are sky-high, but so are the risks.
Is It Too Late to Buy Intellia Therapeutics Stock?
2024 could be an important year for the biotech.